Aquestive posts Q4 net loss of $31.9M; Anaphylm resubmission delayed to Q3 2026

Aquestive Therapeutics, Inc.

Q4 revenue $13.0M (+10% YoY); net loss $31.9M ($0.26/share) incl $13.6M legal; excl legal net loss $18.7M.
Full year 2025 revenue $44.5M (down 23% YoY); net loss $83.8M ($0.78/share) incl $14.3M legal; cash $121.2M.
FY2026 guidance: revenue $46-50M, Non-GAAP adjusted EBITDA loss $35-30M, year-end cash target $70M.
RTW amendment extends Anaphylm deadline to June 30, 2027; warrant for 375k shares at $4; RTW commits $5M stock purchase.
Anaphylm CRL in Jan 2026; NDA resubmission planned Q3 2026 after Type A FDA meeting within 30 days.

item 1.01 item 2.02 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aquestive Therapeutics, Inc. entered into Share Purchase Commitment Agreement with certain RTW-affiliated funds valued at not less than $5,000,000 (effective 2026-03-03).

Action: entry
Agreement: equity purchase
Counterparty: certain RTW-affiliated funds
Value: not less than $5,000,000
Effective: 2026-03-03

Exact text from the filing

The Company also entered into a Share Purchase Commitment Agreement with certain RTW-affiliated funds, pursuant to which such funds committed to purchase, in the aggregate, not less than $5,000,000 of Common Stock during the 90-day period following the effective date of the agreement, at prices determined in accordance with Rule 415(a)(4) under the Securities Act.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aquestive Therapeutics, Inc. entered into Warrant Issuance Agreement with funds managed by RTW (effective 2026-03-03).

Action: entry
Agreement: equity purchase
Counterparty: funds managed by RTW
Effective: 2026-03-03

Exact text from the filing

Concurrently, the Company entered into a Warrant Issuance Agreement with funds managed by RTW pursuant to which the Company agreed to issue a warrant to purchase up to 375,000 shares of the Company's common stock, par value $0.001 per share (the “Common Stock”), at an exercise price of $4.00 per share, expiring on March 3, 2029.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aquestive Therapeutics, Inc. amended Amendment No. 1 to Purchase and Sale Agreement with funds managed by RTW Investments, LP (effective 2026-03-03).

Action: amendment
Agreement: asset purchase
Counterparty: funds managed by RTW Investments, LP
Effective: 2026-03-03

Exact text from the filing

On March 3, 2026, Aquestive Therapeutics, Inc. (the "Company") entered into Amendment No. 1 (the "Amendment") to the Purchase and Sale Agreement (the “Purchase and Sale Agreement”), dated August 13, 2025, with funds managed by RTW Investments, LP ("RTW").

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

Aquestive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001398733-26-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.